Investigating adverse drug events in patients taking blood thinners in the emergency department
Real-life Epidemiology of Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department Setting
This study looks at how often patients on blood thinners experience problems like bleeding or blood clots when they come to the emergency room.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2080 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Besancon Academic / other |
| Locations | 1 site (Besançon) |
| Trial ID | NCT06692504 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence of adverse drug events in patients who are on oral anticoagulation therapy when they present to the emergency department. It focuses on various complications such as traumatic hemorrhage, spontaneous hemorrhage, and thrombosis among patients receiving medications like warfarin and newer anticoagulants. The study will analyze data from patients aged 18 and older admitted to the adult emergency department of Besançon University Hospital over a two-year period. By identifying the frequency and types of adverse events, the study seeks to improve patient safety and management in emergency settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are currently receiving oral anticoagulation therapy and are admitted to the emergency department.
Not a fit: Patients who have discontinued anticoagulant therapy for more than 24 hours prior to admission will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to enhanced safety protocols for patients on anticoagulation therapy, reducing the incidence of serious adverse events.
How similar studies have performed: Previous studies have indicated a high incidence of adverse events related to anticoagulant therapy, suggesting that this area of research is both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Admission to adult emergency department of Besançon University Hospital * Study period: January 1, 2018 to December 31, 2019 * Current oral anticoagulation therapy with: * Acenocoumarol * Apixaban * Dabigatran * Fluindione * Rivaroxaban * Warfarin Exclusion Criterion: \- Discontinuation of anticoagulant therapy for more than 24 hours
Where this trial is running
Besançon
- CHU Besançon — Besançon, France (Recruiting)
Study contacts
- Study coordinator: Omide TAHERI, MD, PhD
- Email: omide.taheri@gmail.com
- Phone: 03 81 66 70 28
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.